Immunotherapy combo shows promise in advanced lung cancer trial
NCT ID NCT03607539
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tested whether adding the immunotherapy drug sintilimab to standard chemotherapy helps people with advanced non-squamous lung cancer live longer without their disease getting worse. About 400 adults with advanced or metastatic non-squamous non-small cell lung cancer took part. The results showed that the combination slowed cancer progression compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, China
Conditions
Explore the condition pages connected to this study.